Ignite Creation Date:
2024-05-06 @ 9:50 AM
Last Modification Date:
2024-10-26 @ 12:20 PM
Study NCT ID:
NCT03093922
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2023-12-28
First Post:
2017-03-23
Brief Title:
A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-03-22
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-03
Completion Date Type:
ESTIMATED
First Submit Date:
2017-03-23
First Submit QC Date:
March 27 2017
Study First Post Date:
2017-03-28
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-27
Last Update Post Date:
2023-12-28
Last Update Post Date Type:
ACTUAL